CG Oncology, Inc. announced that Arthur Kuan, Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, California on Wednesday, January 11, 2023 at 4pm Pacific Standard Time.
IRVINE, Calif.--(BUSINESS WIRE)-- CG Oncology, Inc., an oncolytic immunotherapy company focused on developing novel therapeutics for patients with urologic cancers, today announced that Arthur Kuan, Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, California on Wednesday, January 11, 2023 at 4pm Pacific Standard Time. The presentation will be webcast live and available for replay from the news section of CG Oncology’s website at www.cgoncology.com.
About CG Oncology
CG Oncology is an oncolytic immunotherapy company focused on developing bladder-saving therapeutics for patients with urologic cancer. At CG Oncology, we see a world where urologic cancer patients can benefit from our innovative therapies to live and work with dignity and an enhanced quality of life. To learn more, visit www.cgoncology.com. Follow us on Twitter @cgoncology.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221223005035/en/
Bing Kung
Vice President, Business Development
CG Oncology
bd@cgoncology.com
Media
Kimberly Ha
KKH Advisors
(917) 291-5744
kimberly.ha@kkhadvisors.com
Source: CG Oncology, Inc.
View this news release online at:
http://www.businesswire.com/news/home/20221223005035/en
